Variable | Overall survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
P value | HR (95% CI) | P value | HR (95% CI) | |
Age (yr) | 0.361 | 0.705 (0.332–1.494) | ||
≤ 50 vs > 50 | ||||
Gender | 0.815 | 1.084 (0.552–2.130) | ||
Male vs female | ||||
Tumor diameter (cm) | 0.002** | 2.804 (1.450–5.422) | 0.237 | 1.585 (0.739–3.399) |
≤ 4 vs > 4 | ||||
Tumor location | 0.719 | 0.887 (0.463–1.701) | ||
Up + Middle vs Down | ||||
Tumor differentiation | 0.027* | 2.125 (1.091–4.137) | 0.144 | 1.681 (0.838–3.375) |
High + Middle vs Low | ||||
CEA (ng/ml) | 0.386 | 1.439 (0.632–3.277) | ||
≤ 5 vs > 5 | ||||
CA 19–9 (U/ml) | 0.843 | 0.920 (0.404–2.095) | ||
≤ 37 vs > 37 | ||||
HP infection | 0.918 | 0.967 (0.506–1.846) | ||
− vs + | ||||
T stage | 0.011* | 2.645 (1.245–5.618) | 0.385 | 0.640 (0.234–1.752) |
T1-2 vs T3-4 | ||||
N stage | < 0.0001**** | 5.800 (2.532–13.288) | 0.082 | 2.377 (0.897–6.300) |
N0 vs N1-3 | ||||
HOXA-AS3 in tissues | < 0.0001**** | 6.723 (2.937–15.385) | 0.003** | 4.662 (1.691–12.856) |
High vs Low |